Giuseppe Lopalco (@giuseppelopalc2) 's Twitter Profile
Giuseppe Lopalco

@giuseppelopalc2

Associate Professor in #Rheumatology at @unibait | Member of @official_ASAS and AIDA Network | Editor for @ojrarediseases and @Frontimmunol

ID: 1436680419613810693

linkhttps://pubmed.ncbi.nlm.nih.gov/?term=Lopalco+g&sort=date calendar_today11-09-2021 13:18:12

240 Tweet

477 Followers

449 Following

Giuseppe Lopalco (@giuseppelopalc2) 's Twitter Profile Photo

🔍 Spondiloartriti Assiali: L'Importanza della Diagnosi Precoce🔍 Le spondiloartriti assiali rappresentano una sfida diagnostica, ma riconoscerle in tempo può fare una grande differenza nella gestione della malattia e nella qualità della vita dei pazienti pharmastar.it/pharmastartv//…

Giuseppe Lopalco (@giuseppelopalc2) 's Twitter Profile Photo

Our latest study on RA patients treated with JAK inhibitors reveals a 📈 Herpes Zoster incidence of 2.95 per 100 patient-years. Key predictors: disease duration ⏳, time on JAKi ⌛, and higher disease activity 🔥 mdpi.com/2889928 #mdpijcm via JCM MDPI

Giuseppe Lopalco (@giuseppelopalc2) 's Twitter Profile Photo

📢 Special Issue Alert! 🧬 Exploring Axial Spondyloarthritis (axSpA) & Psoriatic Arthritis (PsA): 🔬 Pathogenetic Mechanisms 🖼️ Advanced Imaging 💊 Innovative Treatments Submit your research! 🌟 mdpi.com/si/212993 #mdpiijms via IJMS MDPI

Giuseppe Lopalco (@giuseppelopalc2) 's Twitter Profile Photo

🚀 Thrilled to share a new work with my friends Vincenzo Venerito & Dr. Fabian Proft ! 🎉 We explore the evolution of #axSpA treatment, from early intervention with biologics and synthetic drugs to personalized strategies for optimal outcomes. 🩺🔬 tandfonline.com/doi/full/10.10…

Giuseppe Lopalco (@giuseppelopalc2) 's Twitter Profile Photo

😍 Excited to participate in the GRAPPA Workshop 2024 in Cagliari! 🌊🌞 I’ll be presenting on “What have we learned from anti-JAK therapy in Psoriatic disease?”🧬💊 A great chance to share insights on PsA and engage with experts. 🤝💡 Thanks to the organizers! 🙏 GRAPPA Network - Official

😍 Excited to participate in the GRAPPA Workshop 2024 in Cagliari! 🌊🌞 I’ll be presenting on “What have we learned from anti-JAK therapy in Psoriatic disease?”🧬💊 A great chance to share insights on PsA and engage with experts. 🤝💡 Thanks to the organizers! 🙏 
<a href="/GrappaO/">GRAPPA Network - Official</a>
Giuseppe Lopalco (@giuseppelopalc2) 's Twitter Profile Photo

🌟 Exciting insights shared today at the GRAPPA Workshop 2024 in beautiful Cagliari! 🇮🇹 Presented data on the efficacy of JAK inhibitors in Psoriatic Arthritis (PsA) 💊, showing significant improvements in VAS pain, PtGA, and PhGA over time 📊 GRAPPA Network - Official

🌟 Exciting insights shared today at the GRAPPA Workshop 2024 in beautiful Cagliari! 🇮🇹 Presented data on the efficacy of JAK inhibitors in Psoriatic Arthritis (PsA) 💊, showing significant improvements in VAS pain, PtGA, and PhGA over time 📊
<a href="/GrappaO/">GRAPPA Network - Official</a>
Giuseppe Lopalco (@giuseppelopalc2) 's Twitter Profile Photo

🧠 New study alert! In collaboration with Prof. Maria Sole Chimenti we explored the prevalence & characteristics of neuropathic pain in #Spondyloarthritis, including axSpA, PsA, & peripheral SpA. 💥 Andrea Cito Maria Sole Chimenti #Rheumatology #ChronicPain #SpA #Research

🧠 New study alert! In collaboration with Prof. <a href="/ChimentiSole/">Maria Sole Chimenti</a> we explored the prevalence &amp; characteristics of neuropathic pain in #Spondyloarthritis, including axSpA, PsA, &amp; peripheral SpA. 💥
<a href="/andrea_cit94/">Andrea Cito</a> <a href="/ChimentiSole/">Maria Sole Chimenti</a> 
#Rheumatology #ChronicPain #SpA #Research
Giuseppe Lopalco (@giuseppelopalc2) 's Twitter Profile Photo

Excited for the upcoming #SIRPuglia 🎉 where we'll discuss real-world data on #Ixekizumab 💉 in #PsoriaticArthritis (PsA) 🔥! Looking forward to exploring its impact on patient outcomes 🙌 and treatment strategies 🧠✨. Let’s advance #Rheumatology together! Lilly Italia

Excited for the upcoming #SIRPuglia 🎉 where we'll discuss real-world data on #Ixekizumab 💉 in #PsoriaticArthritis (PsA) 🔥! Looking forward to exploring its impact on patient outcomes 🙌 and treatment strategies 🧠✨. Let’s advance #Rheumatology together!
<a href="/EliLillyItalia/">Lilly Italia</a>
Seminars in Arthritis and Rheumatism (@seminarthrheum) 's Twitter Profile Photo

From the current issue: A cross-sectional study showing neuropathic pain was prevalent in patients with #spondyloarthritis by Giuseppe Lopalco sciencedirect.com/science/articl…

Giuseppe Lopalco (@giuseppelopalc2) 's Twitter Profile Photo

Neuropathic pain is common among patients with spondyloarthritis (SpA), highlighting the need for accurate diagnosis and personalized therapeutic strategies. PharmaStar Seminars in Arthritis and Rheumatism Maria Sole Andrea Cito Read more: pharmastar.it/news/dolore/do…

Neuropathic pain is common among patients with spondyloarthritis (SpA), highlighting the need for accurate diagnosis and personalized therapeutic strategies.

<a href="/PharmaStar/">PharmaStar</a> 
<a href="/seminarthrheum/">Seminars in Arthritis and Rheumatism</a> 
<a href="/MSoleChimenti/">Maria Sole</a> 
<a href="/andrea_cit94/">Andrea Cito</a> 
Read more: pharmastar.it/news/dolore/do…
Giuseppe Lopalco (@giuseppelopalc2) 's Twitter Profile Photo

🌟 Explore the Complexities of Psoriatic Arthritis! 🌟 📚 This course will focus on: 🔍 Pathogenesis, diagnosis, and management 🩺 Evolving clinical manifestations 📸 The role of imaging and differential diagnosis 🤝 Interdisciplinary collaboration Vincenzo Venerito

🌟 Explore the Complexities of Psoriatic Arthritis! 🌟

📚 This course will focus on:
🔍 Pathogenesis, diagnosis, and management
🩺 Evolving clinical manifestations
📸 The role of imaging and differential diagnosis
🤝 Interdisciplinary collaboration
<a href="/vincevenerito/">Vincenzo Venerito</a>
Giuseppe Lopalco (@giuseppelopalc2) 's Twitter Profile Photo

🎯 Targeting refractory Behçet’s disease: a new therapeutic perspective ✨ Proud to share our latest publication in Internal and Emergency Medicine showcasing the potential of upadacitinib (JAK-1 inhibitor) in managing a challenging case of refractory Behçet’s disease.

🎯 Targeting refractory Behçet’s disease: a new therapeutic perspective

✨ Proud to share our latest publication in Internal and Emergency Medicine showcasing the potential of upadacitinib (JAK-1 inhibitor) in managing a challenging case of refractory Behçet’s disease.
Giuseppe Lopalco (@giuseppelopalc2) 's Twitter Profile Photo

🔬✨ New GISEA Registry Study on Secukinumab in 1045 Psoriatic Arthritis (PsA) Patients ✨🔬 Evaluating effectiveness & treatment persistence across all PsA domains! 📊🩺 pharmastar.it/sharepage.html…

Giuseppe Lopalco (@giuseppelopalc2) 's Twitter Profile Photo

📢 New study on Secukinumab in PsA! 🏥 from GISEA 🔹 63.2% drug survival at 24 months 🔹 Improved disease activity (DAPSA, PASI, ASDAS-CRP) 📉 🔹 Higher persistence in mixed PsA (peripheral+axial) 🔹 Well-tolerated, no serious AEs! 💊✅ Sage Journals 🔗 doi.org/10.1177/175972…

Prof. Denis Poddubnyy (@drpoddubnyy) 's Twitter Profile Photo

ASAS Definition of Difficult-to-Manage including Treatment Refractory Axial Spondyloarthritis is published now! Read the article here: sciencedirect.com/science/articl… or listen to the latest episode of RheumaCast open.spotify.com/show/2LzByQKC1…

ASAS Definition of Difficult-to-Manage including Treatment Refractory Axial Spondyloarthritis is published now! Read the article here: sciencedirect.com/science/articl… or listen to the latest episode of RheumaCast open.spotify.com/show/2LzByQKC1…
Giuseppe Lopalco (@giuseppelopalc2) 's Twitter Profile Photo

🧬 Just published! Our new work with Prof. Denis Poddubnyy, Torsten Diekhoff, Andrea Cito and Dr. Fabian Proft 🦴 We explore the interplay between 🕳️ bone erosion and 🧱 new bone formation in axSpA and PsA Frontiers - Immunology 📚 Read the full article: frontiersin.org/journals/immun…

Giuseppe Lopalco (@giuseppelopalc2) 's Twitter Profile Photo

🚨 Just Published in Sᴡɪss Uʟᴛʀᴀsᴏᴜɴᴅ Cᴇɴᴛᴇʀ - UZR🚨 📢 We’re proud to present the largest real-world study to date on psoriatic arthritis (PsA) patients treated with upadacitinib (UPA) academic.oup.com/rheumatology/a…